Home  |  Contact

Cellosaurus WM115 (CVCL_0040)

Cell line name WM115
Synonyms WM-115; WM 115; WM115F; WM115-mel; WM115mel; WC00079
Accession CVCL_0040
Resource Identification Initiative To cite this cell line use: WM115 (RRID:CVCL_0040)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Part of: Wistar Institute melanoma cell line collection.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: CSF1PO: 11,12->12, D18S51: 17->17,21 and D8S1179: 8,13->13,15.
Misspelling: WH115mel; In CGH-DB 9323-4.
Sequence variations Heterozygous for BRAF p.Val600Asp (c.1799_1800delTGinsAT) (Wistar).
Hemizygous for PTEN deletion (Wistar).
Disease Melanoma (NCIt: C3224)
Derived from metastatic site: Right anterior leg.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_L033 ! WM165-1
CVCL_RN55 ! WM165-2
CVCL_6795 ! WM239A
CVCL_RN56 ! WM239B
CVCL_RN57 ! WM266-1
CVCL_RN58 ! WM266-2
CVCL_RN59 ! WM266-3
CVCL_2765 ! WM266-4
Sex of cell Female
Age at sampling 55Y
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; ESTDAB; Wistar

Markers:
AmelogeninX
CSF1PO12
D13S31712,13
D16S53911,12
D18S5117,21
D19S43313
D21S1129
D2S133819
D3S135815,18
D5S81813
D7S8208
D8S117913,15
FGA21,23
TH017,9
TPOX8,11
vWA15,17
Web pages http://www.proteinatlas.org/learn/cellines
https://www.wistar.org/our-scientists/meenhard-herlyn
http://www.rockland-inc.com/Product.aspx?id=51634
http://tcpaportal.org/mclp/
Publications

PubMed=3856042; DOI=10.1093/jnci/74.2.283
Herlyn M., Balaban G., Bennicelli J., Guerry D. IV, Halaban R., Herlyn D., Elder D.E., Maul G.G., Steplewski Z., Nowell P.C., Clark W.H., Koprowski H.
Primary melanoma cells of the vertical growth phase: similarities to metastatic cells.
J. Natl. Cancer Inst. 74:283-289(1985)

PubMed=4053039
Herlyn M., Thurin J., Balaban G., Bennicelli J.L., Herlyn D., Elder D.E., Bondi E., Guerry D., Nowell P., Clark W.H., Koprowski H.
Characteristics of cultured human melanocytes isolated from different stages of tumor progression.
Cancer Res. 45:5670-5676(1985)

PubMed=3020539; DOI=10.1073/pnas.83.19.7197
Westermark B., Johnsson A., Paulsson Y., Betsholtz C., Heldin C.-H., Herlyn M., Rodeck U., Koprowski H.
Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor.
Proc. Natl. Acad. Sci. U.S.A. 83:7197-7200(1986)

PubMed=2253310; DOI=10.1007/BF00046337
Herlyn M.
Human melanoma: development and progression.
Cancer Metastasis Rev. 9:101-112(1990)

PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x
Tsao H., Goel V., Wu H., Yang G., Haluska F.G.
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
J. Invest. Dermatol. 122:337-341(2004)

PubMed=15467732; DOI=10.1038/sj.onc.1208152
Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J., Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Oncogene 23:8796-8804(2004)

PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x
Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D., Dummer R.
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 19:290-302(2006)

PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235
Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R., Muthusamy V., King A.J., Flaherty K.T., Bosenberg M., Herlyn M., Nathanson K.L.
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Cancer Res. 68:5743-5752(2008)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21424129; DOI=10.3892/or.2011.1220
Manca A., Sini M.C., Izzo F., Ascierto P.A., Tatangelo F., Botti G., Gentilcore G., Capone M., Mozzillo N., Rozzo C., Cossu A., Tanda F., Palmieri G.
Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Oncol. Rep. 25:1495-1502(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ATCC; CRL-1675
Coriell; WC00079 - Discontinued
ECACC; 91061232 - Discontinued
IZSLER; BS TCL 74
Cell line databases/resources CLDB; cl4727
CLDB; cl4728
CCLE; WM115_SKIN
CGH-DB; 9323-4
Cosmic-CLP; 909784
ESTDAB; ESTDAB-066
GDSC; 909784
IGRhCellID; WM115
LINCS_HMS; 50567
LINCS_LDP; LCL-1260
Lonza; 584
Ontologies BTO; BTO:0003075
CLO; CLO_0009613
EFO; EFO_0002390
Chemistry resources ChEMBL-Cells; CHEMBL3308813
ChEMBL-Targets; CHEMBL1075611
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM109022
GEO; GSM827472
GEO; GSM887735
GEO; GSM888830
GEO; GSM1670576
Other Wikidata; Q54994157
Polymorphism and mutation databases Cosmic; 886835
Cosmic; 888868
Cosmic; 897480
Cosmic; 905236
Cosmic; 909784
Cosmic; 932717
Cosmic; 972277
Cosmic; 1155268
Cosmic; 1155547
Cosmic; 1238102
Cosmic; 1238104